CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Solasia Pharma KK is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Solasia Pharma KK
3F, Shiodome Bldg., 1-2-20, Kaigan
Phone: +81 358438045p:+81 358438045 MINATO-KU, TKY  105-0011  Japan Ticker: 45974597
Business Summary
Solasia Pharma KK is a Japan-based company with a product development pipeline of pharmaceuticals and medical devices, and is engaged in the development and sale of pharmaceuticals. Its main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events caused by the administration of malignant tumor treatment drugs and radiation therapy, and improve the treatment of malignant tumors and the quality of life (QOL) of patients. It is engaged in in-licensing of rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates. Its development pipeline includes the transdermal granisetron preparation Sancuso, the organic arsenic preparation darinaparsin, the oral wound dressing protective material episil, and the intracellular superoxide remover PledOx.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Director YoshihiroArai 47 2/1/2013 2/1/2013
Chief Financial Officer, Chief Director of Administration, Director ToshioMiyashita 54 12/1/2015 1/1/2014
Independent Director NorikazuEiki 76 4/1/2016 4/1/2016
Independent Director StanleyLau 68 12/1/2014 12/1/2014
Independent Director JiroMizukawa 70 3/1/2020 3/1/2020

General Information
Number of Employees: 24 (As of 12/31/2023)
Outstanding Shares: 217,949,800 (As of 10/31/2024)
Shareholders: 30,839
Stock Exchange: TYO
Fax Number: +81 367212020


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024